Learning and actioning general principles of cancer cell drug sensitivity

Author:

Carli Francesco,Di Chiaro Pierluigi,Morelli Mariangela,Arora Chakit,Bisceglia Luisa,De Oliveira Rosa Natalia,Cortesi Alice,Franceschi Sara,Lessi Francesca,Di Stefano Anna Luisa,Santonocito Orazio,Pasqualetti Francesco,Aretini Paolo,Miglionico Pasquale,Diaferia Giuseppe R.,Giannotti Fosca,Liò Pietro,Duran-Frigola Miquel,Mazzanti Chiara Maria,Natoli Gioacchino,Raimondi Francesco

Abstract

AbstractHigh-throughput screening platforms for the profiling of drug sensitivity of hundreds of cancer cell lines (CCLs) have generated large datasets that hold the potential to unlock targeted, anti-tumor therapies.In this study, we leveraged these datasets to create predictive models of cancer cells drug sensitivity. To this aim we trained explainable machine learning algorithms by employing cell line transcriptomics to predict the growth inhibitory potential of drugs. We used large language models (LLMs) to expand descriptions of the mechanisms of action (MOA) for each drug starting from available annotations, which were matched to the semantically closest pathways from reference knowledge bases. By leveraging this AI-curated resource, and the interpretability of our model, we demonstrated that pathways enriched for genes crucial for prediction often matched known drug-MOAs and essential genes, suggesting that our models learned the molecular determinants of drug response. Furthermore, we demonstrated that by incorporating only LLM-curated genes associated with MOAs, we enhanced the predictive accuracy of our drug models.To enhance translatability to a clinical setting, we employed a pipeline to align bulk RNAseq from CCLs, used for training the models, to those from patient samples, used for inference. We proved the effectiveness of our approach on TCGA samples, where patients’ best scoring drugs matched those prescribed for their cancer type. We further showed its usefulness by predicting and experimentally validating effective drugs for the patients of two highly lethal solid tumors, i.e. pancreatic cancer and glioblastoma.In summary, our method facilitates the inference and interpretation of cancer cell line drug sensitivity and holds potential to effectively translate them into new cancer therapeutics.Highlights-Interpretable drug-response prediction models were trained on large scale pharmacogenomics data sets (i.e. GDSC and PRISM).-Large language models were used to enhance the curation of biological pathways associated to drugs MOA-Unbiased interpretation of the models demonstrated learning of drug MOAsandgene essentiality-Inference of TCGA cohort samples recovered mono- and combination cancer drug prescriptions and indicate potential repurposing candidates.-Drug candidates predicted from bulk RNAseq samples of pancreatic cancer and glioblastoma were experimentally validated.

Publisher

Cold Spring Harbor Laboratory

Reference54 articles.

1. Ahmad, W. , Simon, E. , Chithrananda, S. , Grand, G. , & Ramsundar, B. (2022). ChemBERTa-2: Towards Chemical Foundation Models. https://arxiv.org/abs/2209.01712v1

2. Optuna

3. The landscape of cancer rewired GPCR signaling axes

4. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3